Subsidized artemisinin based combination treatments for Africa;Associations à base dartémisinine subventionnées pour lAfrique

Medecine et Maladies Infectieuses

Volumn 40, Issue 11, 2010, Pages 611-616

  Fandeur, T ^a   Abani, M ^b  

^a Centre de Recherche Medicale et Sanitaire   (Niger)

^b Ministere de la Sante   (Niger)

Author keywords

ACTs; Affordable medicines facility malaria; Drug resistance; Malaria

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ANTIINFECTIVE AGENT; ARTEMISININ;

AFRICA; ALTERNATIVE MEDICINE; ANTIMALARIAL DRUG RESISTANCE; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HUMAN; MALARIA; MALARIA CONTROL; MONOTHERAPY; MULTIDRUG RESISTANCE; PARASITE TRANSMISSION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THERAPY; DRUG COMBINATION; DRUG RESISTANCE; ECONOMICS; INTERNATIONAL COOPERATION;

AFRICA; ANTI-INFECTIVE AGENTS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; INTERNATIONAL AGENCIES; MALARIA;

EID: 78650175019     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.07.002     Document Type: Review

References (22)

1. World Health Organization: World Malaria report 2008; http://malaria.who.int/wmr2008/malaria2008.pdf.
2. White N.J., Nosten F., Looareesuwan S., Watkins W.M., Marsh K., Snow R.W., et al. Averting a malaria disaster. Lancet 1999, 353:1965-1967.
3. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361(5):455-467.
4. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda MM Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008, 359:2619-2620.
5. Affordable medicines facility-malaria (AMFm). Prepared with guidance from the AMFm Task Force of the Roll Back Malaria Partnership, November 2007. http://www.rollbackmalaria.org/partnership/tf/globalsubsidy/AMFmTechProp osal.pdf.
6. Nosten F., Brasseur P. Combination therapy for malaria: the way forward?. Drugs 2002, 62:1315-1329.
7. Committee on the economics of antimalarial drugs: saving time, buying time: Economics of malaria drugs in an age of resistance. In: Arrow KJ, Panosian C, Gelband H, editors. Committee on the economics of antimalarials; 2004. 388 p. http://www.nap.edu/catalog/11017.html.
8. Müller O., Yé M., Louis V.R., Sié A. Malaria in sub-Saharan Africa. Lancet 2009, 373:122.
9. Sisowath C., Strömberg J., Mårtensson A., Msellem M., Obondo C., Björkman A., et al. In vivo selection of Plasmodium falciparum Pfmdr1 86N coding alleles by artemether-lumefantrine (coartem). J infect Dis 2005, 191:1014-1047.
10. Otten M., Aregawi M., Were W., Karema C., Medin A., Bekele W., et al. Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment. Malar J 2009, 8:14.
11. Ibrahim M.L., Steenkeste N., Khim N., Adam H.H., Konaté L., Coppée J.Y., et al. Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger. Malar J 2009, 8:32.
12. Ministère de la santé du Niger/OMS. Bulletin hebdomadaire de morbidité, de mortalité et de surveillance nutritionnelle, Niger, semaine épidémiologique no 43, 2009; http://www.who.int/hac/crises/ner/sitreps/niger_epi_w43_19_25%20october% 202009.pdf.
13. United nations development programme. Human Development report 2007/2008. Fighting climate change: human solidarity in a divided world. http://hdr.undp.org/en/media/HDR_20072008_EN_Complete.pdf.
14. Julvez J., Develoux M., Mounkaila A., Mouchet J. Diversité du paludisme en zone Sahelo-Saharienne. Une revue à propos de la situation au Niger, Afrique de l'Ouest. Ann Soc Belge Med trop 1992, 72:163-177.
15. Picot S., Olliaro P., de Monbrison F., Bienvenu A.L., Price R.N., Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 2009, 8:89.
16. Hayton K., Su X.-Z. Drug resistance ang genetic mapping in Plasmodium falciparum. Curr Genet 2008, 54:223-239.
17. Guthmann J.P., Checchi F., van den Broek I., Balkan S., van Herp M., Comte E., et al. Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Médecins Sans Frontières. PLoS Med 2008, 5(8):e169.
18. World Health Organisation. Guidelines for the treatment of malaria: second edition. 2010; http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf.
19. Kremsner P.G., Krishna S. Antimalarial combinations. Lancet 2004, 364:285-294.
20. Li G.Q., Guo X.B., Fu L.C., Jian H.X., Wang X.H. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 1994, 88(Suppl. 1):S5-S6.
21. Jambou R., Legrand E., Niang M., Khim N., Lim P., Volney B., et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
22. Boni M.F., Smith D.L., Laxminarayan R. Benefits of using multiple first-line therapies against malaria. PNAS 2008, 105:14216-14221.